We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioTelemetry (BEAT) Scales New 52-Week High on Solid Q2
Read MoreHide Full Article
Share price of BioTelemetry (BEAT - Free Report) rallied to a new 52-week high of $21.42 on Aug 18. This represents an impressive one-year return of approximately 62.6%, better than the S&P 500’s 7.4% over the same period.
Currently, BioTelemetry holds a Zacks Rank #2 (Buy). Notably, the stock has a market cap of $590.21 million.
Catalysts
BioTelemetry reported an impressive second quarter of 2016 with revenues totaling $52.7 million, a 17.5% increase over the prior-year quarter. Notably, adjusted earnings of 20 cents per share beat the Zacks Consensus Estimate by 4 cents and were up 66.6% on a year-over-year basis.
Healthcare and research revenues at BioTelemetry rose by $5.9 million and $2.5 million, respectively. The stock also witnessed an impressive 280 basis points (bps) expansion in gross margin, thanks to volume efficiencies, higher Medicare pricing and stringent cost control for shipping and maintenance.
In addition to the stellar quarterly results, we are looking forward to BioTelemetry’s recent achievements including the 510(k) FDA approval for the next generation MCOT device. We believe that the completion of 8000 CardioKey services, integration of the ePatch business and the successful acquisition of VirtualScopics exclusively fortified the company’s position in research business.
Encouraged by the second-quarter performance and several recent strategic executions, BioTelemetry issued a strong third-quarter 2016 guidance. The company expects revenues in the range of around $53 million to $54 million (up 23% from the year-ago quarter) and adjusted EBITDA return in the band of 22% to 23% (up 38% year over year).
Estimate Revisions
The Zacks Consensus Estimate for fiscal 2016 increased by 8.7% to 75 cents over the last 30 days. Similarly, for fiscal 2017, estimates have scaled 10.5% to 84 cents over the same time frame.
Other Key Picks
Other favorably ranked stocks in the broader medical sector include CryoLife Inc. , Natus Medical and NuVasive Inc. . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BioTelemetry (BEAT) Scales New 52-Week High on Solid Q2
Share price of BioTelemetry (BEAT - Free Report) rallied to a new 52-week high of $21.42 on Aug 18. This represents an impressive one-year return of approximately 62.6%, better than the S&P 500’s 7.4% over the same period.
Currently, BioTelemetry holds a Zacks Rank #2 (Buy). Notably, the stock has a market cap of $590.21 million.
Catalysts
BioTelemetry reported an impressive second quarter of 2016 with revenues totaling $52.7 million, a 17.5% increase over the prior-year quarter. Notably, adjusted earnings of 20 cents per share beat the Zacks Consensus Estimate by 4 cents and were up 66.6% on a year-over-year basis.
Healthcare and research revenues at BioTelemetry rose by $5.9 million and $2.5 million, respectively. The stock also witnessed an impressive 280 basis points (bps) expansion in gross margin, thanks to volume efficiencies, higher Medicare pricing and stringent cost control for shipping and maintenance.
BIOTELEMETRY Price and Consensus
BIOTELEMETRY Price and Consensus | BIOTELEMETRY Quote
In addition to the stellar quarterly results, we are looking forward to BioTelemetry’s recent achievements including the 510(k) FDA approval for the next generation MCOT device. We believe that the completion of 8000 CardioKey services, integration of the ePatch business and the successful acquisition of VirtualScopics exclusively fortified the company’s position in research business.
Encouraged by the second-quarter performance and several recent strategic executions, BioTelemetry issued a strong third-quarter 2016 guidance. The company expects revenues in the range of around $53 million to $54 million (up 23% from the year-ago quarter) and adjusted EBITDA return in the band of 22% to 23% (up 38% year over year).
Estimate Revisions
The Zacks Consensus Estimate for fiscal 2016 increased by 8.7% to 75 cents over the last 30 days. Similarly, for fiscal 2017, estimates have scaled 10.5% to 84 cents over the same time frame.
Other Key Picks
Other favorably ranked stocks in the broader medical sector include CryoLife Inc. , Natus Medical and NuVasive Inc. . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>